AORT
Artivion, Inc.
AORT's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over AORT overall, supported by stronger fundamentals and stronger modeled upside.
AORT Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Weak | |
| Weak |
AORT's revenue is currently stable, but its profitability, cash flow and balance sheet are under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
AORT PE Valuation
AORT has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
AORT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for AORT, with profitability holding steady.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over AORT on the outlook, with more favorable profitability expectations.
AORT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.05 | — |
| Q3 2026 | -$0.35 | -$0.10 |
| Q2 2026 | -$0.06 | +$0.37 |
| Q1 2026 | $0.25 | +$0.76 |
| Q4 2025 | $0.21 | +$0.53 |
| Q3 2025 | -$0.25 | -$0.23 |
| Q2 2025 | -$0.43 | -$0.22 |
| Q1 2025 | -$0.51 | -$0.27 |
| Q4 2024 | -$0.32 | +$0.43 |
AORT is still losing money, but far less than before: $0.35 per share over the past year, against $1.03 at its worst in late 2022.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over AORT on earnings quality, reporting a profit while its opponent remains loss making.
AORT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $123.8M | +9.2% |
| Q2 2026 | $125.8M | +11% |
| Q1 2026 | $116.3M | +18% |
| Q4 2025 | $116M | +19% |
| Q3 2025 | $113.4M | +18% |
| Q2 2025 | $113M | +15% |
| Q1 2025 | $99M | +1.6% |
| Q4 2024 | $97.3M | +3.9% |
AORT's revenue has grown year over year for 23 quarters in a row: $124M last quarter, up 9.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.4% | -8.7 points |
| Q2 2026 | -6.7% | -14 points |
| Q1 2026 | 5% | +2.8 points |
| Q4 2025 | 9.2% | +6.5 points |
| Q3 2025 | 11% | +6.5 points |
| Q2 2025 | 7.4% | +0.8 points |
| Q1 2025 | 2.2% | -24 points |
| Q4 2024 | 2.7% | -0.6 points |
AORT's operating margin was 2.4% last quarter, down 8.7 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over AORT on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over AORT on profitability, with a higher operating margin.
AORT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$17.6M | -200% |
| Q2 2026 | -$12M | -202% |
| Q1 2026 | -$6.8M | +$13.7M |
| Q4 2025 | -$7.9M | -191% |
| Q3 2025 | $17.7M | +126% |
| Q2 2025 | $11.7M | +224% |
| Q1 2025 | -$20.6M | -$11.5M |
| Q4 2024 | $8.7M | -2.2% |
AORT's free cash flow was −$44M over the past year, against $18M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over AORT on cash generation, producing positive trailing cash flow while its opponent burns cash.
AORT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +177K shares |
| 1 year | -0.1% | -57K shares |
| 3 years | +19% | +7.8M shares |
| 5 years | +9.6% | +4.3M shares |
| Available history | +29% | +10.9M shares |
AORT has 49M diluted shares, about the same as a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over AORT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
AORT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 8.5x | High |
| Q2 2026 | 6.3x | High |
| Q1 2026 | 2.6x | Moderate |
| Q4 2025 | 2.7x | Moderate |
| Q3 2025 | 2.9x | Moderate |
| Q2 2025 | 4.0x | Elevated |
| Q1 2025 | 7.0x | High |
| Q4 2024 | 4.1x | High |
AORT's net debt is about 8.5 years of its operating earnings (EBITDA), up from 2.9 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over AORT on leverage, with a lower net debt burden relative to earnings.
AORT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.0 | Neutral |
| Stochastic | 10.1 | Oversold |
AORT's weekly RSI is 31 (neutral) and its Stochastic is 10 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
AORT PE vs Healthcare Sector
| Metric | AORT | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
AORT has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
AORT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $21.7 | 11% below |
| 20 week MA | $24.2 | 20% below |
| 50 week MA | $30.8 | 37% below |
| 100 week MA | $32.0 | 39% below |
| 200 week MA | $25.7 | 24% below |
AORT is in a downtrend: it's below all five of its weekly moving averages, and 24% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over AORT on trend strength, trading above more of its moving averages.
AORT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $26.7 | $23.5 | -12% |
| 2021 | $23.5 | $20.4 | -14% |
| 2022 | $20.4 | $11.8 | -42% |
| 2023 | $11.8 | $17.9 | +51% |
| 2024 | $17.9 | $29.0 | +62% |
| 2025 | $29.0 | $46.3 | +60% |
| 2026 YTD | $46.3 | $19.4 | -58% |
AORT has finished lower in three of the last six years. It's down 58% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over AORT on returns for 2026, with the stronger performance.